Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Kazuki Hashimoto Last modified date:2023.11.02

Assistant Professor / Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University / Otorhinolaryngology Head and Neck Surgery / Kyushu University Hospital


Papers
1. Matsuo M, Masuda M, Yamauchi M, Taura M, Hashimoto K, Kogo R, Jiromaru R, Hongo T, Manako T, Nakagawa T., Pembrolizumab Monotherapy Versus Pembrolizumab Plus Chemotherapy in Patients With Head and Neck Squamous Cell Carcinoma, In Vivo, 10.21873/invivo.13318., 37, 5, 2188-2196, 2023.09.
2. Wakasaki T, Yasumatsu R, Tanabe M, Yoshikawa H, Jiromaru R, Hashimoto K, Matsuo M, Fujimura A, Nakagawa T., Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights, In Vivo., 10.21873/invivo.13198., 37, 3, 1219-1225, 2023.05.
3. Takafumi Nakano, Ryuji Yasumatsu, Kazuki Hashimoto, Ryosuke Kuga, Takahiro Hongo, Hidetaka Yamamoto, Mioko Matsuo, Takahiro Wakasaki, Rina Jiromaru, Tomomi Manako, Satoshi Toh, Muneyuki Masuda, Moriyasu Yamauchi, Yuichiro Kuratomi, Masahiko Taura, Toranoshin Takeuchi, Takashi Nakagawa, Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study., Anticancer research, 10.21873/anticanres.15854, 42, 7, 3653-3664, 2022.07, BACKGROUND/AIM: This study investigated the effectiveness of pembrolizumab with or without chemotherapy on advanced-stage head and neck cancer (HNC), including nasopharyngeal, sinonasal cavity and external auditory canal cancer, in a real-world setting. PATIENTS AND METHODS: We retrospectively collected data from 97 HNC patients who were treated with pembrolizumab alone (n=60) or with chemotherapy (n=37), and we investigated the association between clinicopathological findings and treatment response or prognosis. RESULTS: Patients treated with pembrolizumab and chemotherapy had a 1-year overall survival (OS) of 72.8%, objective response rate (ORR) of 48.6%, and serious (≥G3) adverse events (AEs) of 29.7%. Patients treated with pembrolizumab alone had a 1-year OS of 51.9%, ORR of 21.7%, and ≥G3 AEs of 6.7%. Both the ORR and disease control rate (DCR) in the pembrolizumab with chemotherapy group were significantly better than those in the pembrolizumab group (p=0.074 and p=0.00101, respectively). Among patients with distant metastasis, patients on pembrolizumab with chemotherapy achieved significantly better OS than pembrolizumab alone (p=0.0039). Among patients in the pembrolizumab group, both AE-positive and better performance status were associated with longer OS (p=0.011 and p=0.0037, respectively). CONCLUSION: Our real-world experience reinforces the durability and effectiveness of pembrolizumab for HNC patients. Additionally, our results suggest that pembrolizumab with chemotherapy might be recommended for patients with distant metastasis and no prior treatment. Further studies are needed to determine the optimal treatment strategy for HNC..
4. Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T., Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer, In Vivo, 10.21873/invivo.12790, 36, 2, 2022.04.
5. Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T., Treatment efficacy of PD-1 inhibitor therapy in patients with recurrent and/or metastatic salivary gland carcinoma, Anticancer Res, 10.21873/anticanres.15558, 42, 2, 981-989, 2022.02.
6. Jiromaru R, Yasumatsu R, Yamamoto H, Kuga R, Hongo T, Nakano T, Manako T, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T., A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience, Eur Arch Otorhinolaryngol, 10.1007/s00405-021-07236-z, 2022.01.
7. Takahiro Hongo, Hidetaka Yamamoto, Mika Tanabe, Ryuji Yasumatsu, Ryosuke Kuga, Yoshiko Miyazaki, Rina Jiromaru, Kazuki Hashimoto, Yuki Tateishi, Koh-Hei Sonoda, Takashi Nakagawa, Yoshinao Oda, High-risk HPV-related Squamous Cell Carcinoma in the Conjunctiva and Lacrimal sac: Clinicopathologic Characteristics and Diagnostic Utility of p16 and Rb Immunohistochemistry., The American journal of surgical pathology, 10.1097/PAS.0000000000001857, 46, 7, 977-987, 2022.01, High-risk human papillomavirus (HPV) infection in conjunctival and lacrimal sac squamous cell carcinomas (SCCs) has been sporadically reported; however, its prevalence, clinicopathologic significance and surrogate markers have not been fully elucidated. Here, we attempted to clarify these questions in Japanese patients with conjunctiva and lacrimal sac SCCs. We retrospectively collected 51 conjunctival SCC and 7 lacrimal sac SCC samples and analyzed them for (1) transcriptionally active high-risk HPV infection using messenger RNA in situ hybridization and (2) protein expressions of p16 and Rb using immunohistochemistry (IHC). Among a total of 58 cases, 25 (43.1%) and 16 (27.6%) tumors were positive for p16-IHC and HPV in situ hybridization, respectively. Ten (19.6%) of the 51 conjunctival SCCs, especially in the palpebral conjunctiva, and 6 (85.7%) of the 7 lacrimal sac SCCs were positive for high-risk HPV. High-risk HPV infection was significantly associated with younger patients, nonkeratinizing SCC histology, p16-positivity and partial loss of Rb expression, but not with recurrence risk. Notably, p16-IHC was not a perfect surrogate marker for high-risk HPV infection; only 64% (16/25) of p16-positive tumors were positive for high-risk HPV. In contrast, the p16+/Rb partial loss pattern was exclusively correlated with high-risk HPV-positivity. The results suggest that the combination of p16 and Rb expression patterns by IHC could be a useful method to predict high-risk HPV infection in conjunctival and lacrimal sac SCCs. HPV infection may be of less prognostic value in this field of cancers..
8. Yasumatsu R, Manako T, Jiromaru R, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T., Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis, Ear Nose Throat J, 10.1177/01455613211013084. , 2021.04.
9. Uchi R, Jiromaru R, Yasumatsu R, Yamamoto H, Hongo T, Manako T, Sato K, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T., Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma, Anticancer Res, 10.21873/anticanres.14752., 2021.01.
10. Yasumatsu R, Matsuo M, Wakasaki T, Masuda M, Takeuchi T, Manako T, Jiromaru R, Uchi R, Hashimoto K, Nakagawa T., Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events, Acta Otolaryngol, 10.1080/00016489.2020.1807601., 140, 12, 2020.12.
11. Hashimoto K, Hayashi R, Mukaigawa T, Yamazaki M, Fujii S., Concomitant expression of ezrin and HER2 predicts distant metastasis and poor prognosis of patients with salivary gland carcinomas, Human Pathology, 63, 110-119, 2017.05.
12. Nakashima T, Yasumatsu R, Toh S, Hashimoto K, Shinoto M, Nakamura K, Komune S., Is there a role of adjuvant treatment for salivary duct carcinoma?, J Laryngol Otol, 2015.03.
13. Yamauchi M, Nakano T, Nakashima T, Yasumatsu R, Hashimoto K, Toh S, Shiratsuchi H, Oda Y, Komune S., Interferon Inducible IFI16 Expression in p16 Positive Squamous Cell Carcinoma of the Oropharynx, ISRN Otolaryngol, 2013.10.